Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
LYEL
LYEL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LYEL News
Lyell Immunopharma Launches PiNACLE-H2H Clinical Trial for Ronde-cel
4d ago
Newsfilter
Mineralys Therapeutics Shares Surge 203.4%, NDA Submission Expected in 2026
Dec 26 2025
NASDAQ.COM
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Dec 24 2025
Globenewswire
Lyell Immunopharma Soars Following Recent ASH Data and Immunotherapy Growth
Dec 22 2025
SeekingAlpha
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg Dose
Dec 19 2025
PRnewswire
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Dec 19 2025
Newsfilter
Lyell Immunopharma Stock Increases Following HC Wainwright Upgrade
Dec 09 2025
Yahoo Finance
Eaton Analyst Becomes Optimistic; Check Out Tuesday's Top 5 Upgrades
Dec 09 2025
Benzinga
Lyell's Ronde-cel Demonstrates Long-lasting Complete Responses and Acceptable Safety in High-Risk LBCL Patients
Dec 08 2025
NASDAQ.COM
Lyell Immunopharma Reports 93% Overall Response Rate in Large B-Cell Lymphoma Trials
Dec 07 2025
Globenewswire
Lyell Immunopharma Reports 93% Overall Response Rate for Ronde-cel in Large B-Cell Lymphoma Trials
Dec 07 2025
Newsfilter
HC Wainwright & Co. Keeps Neutral Rating on Lyell Immunopharma and Increases Price Target to $20
Nov 24 2025
Benzinga
Analyst Starts Coverage on United Therapeutics with Optimism; Check Out the Top 5 Initiations for Friday
Sep 26 2025
Benzinga
Lyell Immunopharma: Q2 Earnings Snapshot
Aug 12 2025
Yahoo Finance
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
Jul 29 2025
Newsfilter
Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Jun 24 2025
Benzinga
Show More News
